InvestIdeas

08/31/2015 Sell To Close 100 SPY SepWk1 195 Put $1.65 $16,347.34

08/31/2015 Buy To Open 100 SPY SepWk1 195 Put $1.42 ($14,352.35)

Total $1,994.99

=> my 'virgin' Put Option trade tonight ...

Executed an OCUL long Call (which took a day to fill) Mar16 25 Call.

I would also do an underlying stock purchase at entry price of 13.5 (ranging to 15.5).

Various reasons, good pipeline and potential clinical PhIII trial announcement.

And changed my strategy tonight. Considering that there might be a technical rebound prior to the FED meeting on 16-17 next week.

Bought a short Call SPY Sep15 198.5

Hope I am spot on.

09/03/2015 O STC SPY Sep15 198.5 Call 50 $2.52 $12,523.58
09/01/2015 O BTO SPY Sep15 198.5 Call 50 $2.01 ($10,126.18) $2,397.40

Total Realized Gain/Loss for SPY $2,397.40

Glad that my two trades were up-to-expectations ...
I'm going to bed now --- today, I am almost like a walking zombie in daylight (!)

Vested in OCUL stock last night.

Approx. half of its market capital was wiped out last Thurs since its announcement re. its disappointment in the clinical trial of dexamethasone (allergic conjunctivitis) with mix results as compared to the control drug timolol ...

Apply reverse thinking, one shall see that the volume of sellers had decreased, and 2.4 Mil of shares had changed hands ...

initiated 28 Oct OCUL @ 7.8,

stacked on 30 Oct OCUL @ 8.9, and

exited 02 Nov @ 9.3.

(I may swing in for a small trade if the gap is closed)

important dates are 04, 11 and 12 and 17 Nov, esp. 11 is the quarter earning announcement.

maybe, I sold OCUL too early. haa.

next watch-list is NVTA (Invitae), ie. I've been reading about it ad-hoc basis since Feb.

Re. VRX

Worthwhile to sell Puts now?

Another round of hedge funds selling triggered the drastic drop ... now it is a clear trend that there is no support (no matter Charles M. or news reports regarding the CEO ...)

One just need to make an educated guess on the Strike Price and the Option Term ... 60 by end of Nov?

Re. OCUL, vested (again) @ 9.3

The set date for an FDA approval is Jul 2016. Currently in review, hence may see potential signalling. Earning announcement in Mar.

the March results were not impressive.

however trade this in-bet some dips, with a view on their pipe and potential fda approval in July.

bought some and exited @ 12.36-12.50.